149 related articles for article (PubMed ID: 38480816)
1. Impact of LKB1 status on radiation outcome in patients with stage III non-small-cell lung cancer.
Sitthideatphaiboon P; Nantavithya C; Chantranuwat P; Vinayanuwattikun C; Sriuranpong V
Sci Rep; 2024 Mar; 14(1):6146. PubMed ID: 38480816
[TBL] [Abstract][Full Text] [Related]
2.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
4. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
5. Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer.
Rajpara RS; Schreibmann E; Fox T; Stapleford LJ; Beitler JJ; Curran WJ; Higgins KA
Radiat Oncol; 2014 Aug; 9():187. PubMed ID: 25154893
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
7. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
[TBL] [Abstract][Full Text] [Related]
8. LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.
Avilés-Salas A; Díaz-García DA; Lara-Mejía L; Cardona AF; Orozco-Morales M; Catalán R; Hernández-Pedro NY; Rios-Garcia E; Ramos-Ramírez M; Arrieta O
Curr Oncol; 2022 Dec; 30(1):333-343. PubMed ID: 36661676
[TBL] [Abstract][Full Text] [Related]
9. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
10. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
11. The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer.
Kamran SC; Coroller T; Milani N; Agrawal V; Baldini EH; Chen AB; Johnson BE; Kozono D; Franco I; Chopra N; Zeleznik R; Aerts HJWL; Mak R
Radiat Oncol; 2020 Jan; 15(1):14. PubMed ID: 31937336
[TBL] [Abstract][Full Text] [Related]
12. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
[TBL] [Abstract][Full Text] [Related]
13. A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Sebastian NT; Webb A; Shilo K; Robb R; Xu-Welliver M; Haglund K; Brownstein J; DeNicola GM; Shen C; Williams TM
Cancer; 2023 Dec; 129(24):3971-3977. PubMed ID: 37560930
[TBL] [Abstract][Full Text] [Related]
14. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
15. The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy.
Gul K; Mehmet K; Meryem A
Clin Nutr; 2017 Aug; 36(4):1022-1028. PubMed ID: 27373496
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
Mak RH; Doran E; Muzikansky A; Kang J; Neal JW; Baldini EH; Choi NC; Willers H; Jackman DM; Sequist LV
Oncologist; 2011; 16(6):886-95. PubMed ID: 21632451
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
[TBL] [Abstract][Full Text] [Related]
19. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
20. Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Lim YJ; Chang JH; Kim HJ; Keam B; Kim TM; Kim DW; Paeng JC; Kang KW; Chung JK; Jeon YK; Chung DH; Wu HG
Clin Lung Cancer; 2017 May; 18(3):e169-e178. PubMed ID: 28131636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
